These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 33892410)

  • 1. The European Union and personalised cancer medicine.
    Hickman JA; Tannock IF; Meheus L; Hutchinson L
    Eur J Cancer; 2021 Jun; 150():95-98. PubMed ID: 33892410
    [TBL] [Abstract][Full Text] [Related]  

  • 2. National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network.
    Abrams J; Conley B; Mooney M; Zwiebel J; Chen A; Welch JJ; Takebe N; Malik S; McShane L; Korn E; Williams M; Staudt L; Doroshow J
    Am Soc Clin Oncol Educ Book; 2014; ():71-6. PubMed ID: 24857062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is Precision Medicine an Oxymoron?
    Eckhardt SG; Lieu C
    JAMA Oncol; 2019 Feb; 5(2):142-143. PubMed ID: 30419105
    [No Abstract]   [Full Text] [Related]  

  • 4. Rare Mutations in Cancer Drug Resistance and Implications for Therapy.
    Beckman RA; Loeb LA
    Clin Pharmacol Ther; 2020 Sep; 108(3):437-439. PubMed ID: 32648584
    [No Abstract]   [Full Text] [Related]  

  • 5. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
    Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
    Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Roles of tumor heterogeneity in the development of drug resistance: A call for precision therapy.
    Wu D; Wang DC; Cheng Y; Qian M; Zhang M; Shen Q; Wang X
    Semin Cancer Biol; 2017 Feb; 42():13-19. PubMed ID: 27840278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New ESMO scale ranks mutations as cancer medicine targets.
    Fricker J
    Lancet Oncol; 2018 Oct; 19(10):e513. PubMed ID: 30177495
    [No Abstract]   [Full Text] [Related]  

  • 8. Implications of intratumour heterogeneity for treatment stratification.
    Crockford A; Jamal-Hanjani M; Hicks J; Swanton C
    J Pathol; 2014 Jan; 232(2):264-73. PubMed ID: 24115146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-depth sequencing of paired primary and metastatic tumours: Implications for personalised medicine.
    Grellety T; Lucchesi C; Hostein I; Auzanneau C; Khalifa E; Soubeyran I; Italiano A
    Eur J Cancer; 2017 Oct; 84():250-256. PubMed ID: 28841542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maurie Markman on the Groundbreaking TAPUR Trial.
    Markman M
    Oncology (Williston Park); 2017 Mar; 31(3):158, 168. PubMed ID: 28299751
    [No Abstract]   [Full Text] [Related]  

  • 11. Precision cancer medicine: the future is now, only better.
    Tsimberidou AM; Eggermont AM; Schilsky RL
    Am Soc Clin Oncol Educ Book; 2014; ():61-9. PubMed ID: 24857061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The genetic complexity of common cancers and the promise of personalized medicine: is there any hope?
    Arnedos M; Vielh P; Soria JC; Andre F
    J Pathol; 2014 Jan; 232(2):274-82. PubMed ID: 24114621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using Somatic Mutations to Guide Treatment Decisions: Context Matters.
    Horlings HM; Shah SP; Huntsman DG
    JAMA Oncol; 2015 Jun; 1(3):275-6. PubMed ID: 26181166
    [No Abstract]   [Full Text] [Related]  

  • 14. New clinical trial designs in the era of precision medicine.
    Garralda E; Dienstmann R; Piris-Giménez A; Braña I; Rodon J; Tabernero J
    Mol Oncol; 2019 Mar; 13(3):549-557. PubMed ID: 30698321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer Genetics and Implications for Clinical Management.
    Jamieson NB; Chang DK; Biankin AV
    Surg Clin North Am; 2015 Oct; 95(5):919-34. PubMed ID: 26315514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Delivering on the promise of precision cancer medicine.
    Berger MF; Van Allen EM
    Genome Med; 2016 Oct; 8(1):110. PubMed ID: 27782852
    [No Abstract]   [Full Text] [Related]  

  • 17. Precision Medicine in Pediatric Oncology.
    Vo KT; Parsons DW; Seibel NL
    Surg Oncol Clin N Am; 2020 Jan; 29(1):63-72. PubMed ID: 31757314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anticipating designer drug-resistant cancer cells.
    Frangione ML; Lockhart JH; Morton DT; Pava LM; Blanck G
    Drug Discov Today; 2015 Jul; 20(7):790-3. PubMed ID: 25697478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Basket trials: From tumour gnostic to tumour agnostic drug development.
    Dittrich C
    Cancer Treat Rev; 2020 Nov; 90():102082. PubMed ID: 33096345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Personalized Medicine: Genomics Trials in Oncology.
    Hayes DF; Schott AF
    Trans Am Clin Climatol Assoc; 2015; 126():133-43. PubMed ID: 26330667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.